LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stake Cut by Fifth Third Bancorp

Fifth Third Bancorp lessened its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,657 shares of the medical instruments supplier’s stock after selling 435 shares during the quarter. Fifth Third Bancorp’s holdings in LeMaitre Vascular were worth $982,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in LMAT. Glenmede Trust Co. NA grew its position in LeMaitre Vascular by 1.3% during the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock valued at $976,000 after purchasing an additional 136 shares in the last quarter. Summit Global Investments grew its holdings in shares of LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after acquiring an additional 146 shares in the last quarter. NBC Securities Inc. increased its stake in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares in the last quarter. Finally, MML Investors Services LLC boosted its position in LeMaitre Vascular by 2.8% during the third quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock valued at $660,000 after purchasing an additional 191 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $99.92 on Thursday. The stock has a 50-day simple moving average of $97.82 and a 200 day simple moving average of $92.68. LeMaitre Vascular, Inc. has a twelve month low of $56.61 and a twelve month high of $109.58. The stock has a market capitalization of $2.25 billion, a PE ratio of 54.60, a P/E/G ratio of 2.15 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.33 earnings per share. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of recent research reports. Barrington Research raised their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.